Brodsky & Smith Investigates Proposed Acquisition of QIAGEN N.V.
Law firm Brodsky & Smith has announced an investigation into the proposed acquisition of QIAGEN N.V. by EQT Private Equity.
Stocks · News reference
Citigroup Maintains Neutral on Qiagen, Raises Price Target to $52
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends, and Forecast - 2026 to 2036 | Precision Medicine Drives 12.7% CAGR and a $305.21 Million Opportunity
Thailand's NGS market is projected to reach $305.21 million by 2036, growing at a 12.7% CAGR from $92.03 million in 2026. Growth is driven by the Genomics Thailand national precision medicine initiative, rising clinical adoption in oncology and rare diseases, expanded reimbursement under the Universal Coverage Scheme, and increasing demand for outsourced sequencing services. Commercial sequencing services and clinical applications in oncology are expected to be the fastest-growing segments.
Barclays Downgrades QIAGEN to Equal Weight
Barclays Capital downgraded QIAGEN N.V. from "Overweight" to "Equal Weight" and reduced its price target for the company's shares from $55 to $53.